Data on all generic drug entries in the period 1984-1994 are used to estimate which markets heterogeneous potential entrants will decide to enter. I find that organizational experience predicts entry. Firms tend to enter markets with supply and demand characteristics similar to the firm's...

I use data on all generic drug approvals granted from 1984- 1994 to examine whether generic entrants are choosing to enter markets based on the characteristics of their current portfolio of drugs. The findings suggest that a firm's previous experience with a drug or therapy reduces its cost of...

Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry, however only a few biosimilars have been approved in the US since 2015, thereby largely preserving biologics...